{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:30:46Z","timestamp":1794573046777,"version":"4.9.1"},"reference-count":44,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Kaposi sarcoma\u2013associated herpesvirus (KSHV) inflammatory cytokine syndrome (KICS) is characterized by KSHV infection and severe inflammatory symptoms and signs (elevated cytokines, C-reactive protein, and KSHV viremia), without evidence of other causes. The primary objective of this study was to evaluate KICS natural history after exclusion of other inflammatory disorders, including multicentric Castleman disease (MCD) and, per a revised working definition, primary effusion lymphoma (PEL). Participants with KICS were treated for concurrent Kaposi sarcoma (KS) and\/or received KICS-directed treatment with targeted therapies used in other KSHV-associated disorders (KAD), such as rituximab, tocilizumab, or high-dose valganciclovir\/azidothymidine. KICS response was evaluated using the Clinical Benefit Response Criteria (KICS-CBR). Baseline inflammatory cytokines were compared between those with KICS and participants with other KAD. Seventy-three participants were enrolled from 2011 to 2022. Following exclusion of other inflammatory processes, 35 (34 with HIV) had KICS, and all but 1 had concurrent stage T1 KS. Among participants with KICS, 11 (43%) received rituximab (with liposomal doxorubicin [8] or paclitaxel [3] for concurrent KS) and 55% (95% confidence interval [CI], 23%-83%) had a response per KICS-CBR. Interleukin-10 (IL-10), IL-6, and IL-1\u03b2 levels were higher among those with KICS than those with KS alone. The median overall survival among participants with KICS was 5.7 years (95% CI, 5.7 years to not reached). KICS is a diagnosis of exclusion from PEL and MCD. Nearly all patients with KICS have advanced KS, and the syndrome is associated with significant morbidity and mortality. Rituximab may benefit a subset of participants with KICS. This trial was registered at www.clinicaltrials.gov as #NCT01419561.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016685","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T19:08:44Z","timestamp":1754420924000},"page":"5720-5731","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Characteristics and outcomes of Kaposi sarcoma herpesvirus\u2013associated inflammatory cytokine syndrome"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5709-4675","authenticated-orcid":false,"given":"Ramya","family":"Ramaswami","sequence":"first","affiliation":[{"name":"1HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5794-7292","authenticated-orcid":false,"given":"Kathryn","family":"Lurain","sequence":"additional","affiliation":[{"name":"1HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N.","family":"Polizzotto","sequence":"additional","affiliation":[{"name":"1HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaida","family":"Widell","sequence":"additional","affiliation":[{"name":"1HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ekwede","sequence":"additional","affiliation":[{"name":"1HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tassi","sequence":"additional","affiliation":[{"name":"1HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Rupert","sequence":"additional","affiliation":[{"name":"2AIDS Monitoring Laboratory, Leidos Biomedical Research, Frederick, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie A.","family":"Marshall","sequence":"additional","affiliation":[{"name":"3Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Roth","sequence":"additional","affiliation":[{"name":"4Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando C.","family":"Filie","sequence":"additional","affiliation":[{"name":"4Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-1439","authenticated-orcid":false,"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[{"name":"4Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-0301","authenticated-orcid":false,"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"4Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5408-9253","authenticated-orcid":false,"given":"Hao-Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"4Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Whitby","sequence":"additional","affiliation":[{"name":"3Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Uldrick","sequence":"additional","affiliation":[{"name":"1HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-1395","authenticated-orcid":false,"given":"Robert","family":"Yarchoan","sequence":"additional","affiliation":[{"name":"1HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"5192","key":"2025112508561948900_bib1","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1126\/science.7997879","article-title":"Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi\u2019s sarcoma","volume":"266","author":"Chang","year":"1994","journal-title":"Science"},{"issue":"4","key":"2025112508561948900_bib2","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.V86.4.1276.bloodjournal8641276","article-title":"Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease [see comments]","volume":"86","author":"Soulier","year":"1995","journal-title":"Blood"},{"issue":"18","key":"2025112508561948900_bib3","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi's sarcoma\u2013associated herpesvirus-like DNA sequences in AIDS-related body-cavity\u2013based lymphomas","volume":"332","author":"Cesarman","year":"1995","journal-title":"N Engl J Med"},{"issue":"14","key":"2025112508561948900_bib4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJM199510053331417","article-title":"Herpes-like DNA sequences in a body-cavity\u2013based lymphoma in an HIV-negative patient","volume":"333","author":"Nador","year":"1995","journal-title":"N Engl J Med"},{"issue":"16","key":"2025112508561948900_bib5","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2019-01-893339","article-title":"Viral, immunologic, and clinical features of primary effusion lymphoma","volume":"133","author":"Lurain","year":"2019","journal-title":"Blood"},{"issue":"26","key":"2025112508561948900_bib6","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1182\/blood-2013-08-519959","article-title":"Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"122","author":"Polizzotto","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2025112508561948900_bib7","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1182\/bloodadvances.2020004058","article-title":"Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases","volume":"5","author":"Ramaswami","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2025112508561948900_bib8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1086\/654798","article-title":"An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without multicentric Castleman disease","volume":"51","author":"Uldrick","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2025112508561948900_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fmicb.2012.00073","article-title":"Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV\u2013MCD) and the KSHV inflammatory cytokine syndrome","volume":"3","author":"Polizzotto","year":"2012","journal-title":"Front Microbiol"},{"issue":"26","key":"2025112508561948900_bib10","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1182\/blood-2010-11-317610","article-title":"High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy","volume":"117","author":"Uldrick","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2025112508561948900_bib11","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood.2019004602","article-title":"Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"135","author":"Ramaswami","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2025112508561948900_bib12","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/14787210.2023.2247161","article-title":"Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies","volume":"21","author":"Patel","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"2025112508561948900_bib13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ996","article-title":"Clinical features and outcomes of patients with symptomatic Kaposi sarcoma herpesvirus (KSHV)-associated inflammation: prospective characterization of KSHV inflammatory cytokine syndrome (KICS)","volume":"62","author":"Polizzotto","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2025112508561948900_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ajcp\/aqw218","article-title":"HHV8\/KSHV-positive lymphoproliferative disorders and the spectrum of plasmablastic and plasma cell neoplasms: 2015 SH\/EAHP Workshop Report-Part 3","volume":"147","author":"Chadburn","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"2025112508561948900_bib15","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumours Lyon, France","year":"2017","edition":"4th ed"},{"issue":"4","key":"2025112508561948900_bib16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bjh.18518","article-title":"A novel approach for characterization of KSHV-associated multicentric Castleman disease from effusions","volume":"200","author":"Zhou","year":"2023","journal-title":"Br J Haematol"},{"issue":"14","key":"2025112508561948900_bib17","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1158\/1078-0432.CCR-18-3528","article-title":"A pilot study of liposomal doxorubicin combined with bevacizumab followed by bevacizumab monotherapy in patients with advanced Kaposi sarcoma","volume":"25","author":"Ramaswami","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2025112508561948900_bib18","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1158\/1078-0432.CCR-21-3364","article-title":"Safety, activity, and long-term outcomes of pomalidomide in the treatment of Kaposi sarcoma among individuals with or without HIV infection","volume":"28","author":"Ramaswami","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025112508561948900_bib19","unstructured":"National Comprehensive Cancer Network\n          . AIDS-related Kaposi sarcoma (version 1.2018). Accessed 12 August 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kaposi.pdf."},{"key":"2025112508561948900_bib20","unstructured":"National Comprehensive Cancer Network\n          . B-cell lymphomas - version 4.2021-May 5, 2021. Accessed 12 August 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"2025112508561948900_bib21","unstructured":"Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Accessed 15 June 2024. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-opportunistic-infection\/."},{"key":"2025112508561948900_bib22","author":"Uldrick","year":"2014"},{"issue":"3","key":"2025112508561948900_bib23","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/cid\/ciz877","article-title":"Prospective international study of incidence and predictors of immune reconstitution inflammatory syndrome and death in people living with human immunodeficiency virus and severe lymphopenia","volume":"71","author":"Sereti","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2025112508561948900_bib24","doi-asserted-by":"crossref","first-page":"ofx196","DOI":"10.1093\/ofid\/ofx196","article-title":"Experience with Kaposi sarcoma herpesvirus inflammatory cytokine syndrome in a large urban HIV clinic in the United States: case series and literature review","volume":"4","author":"Cantos","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"2025112508561948900_bib25","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/cid\/ciz250","article-title":"Kaposi Sarcoma herpesvirus inflammatory cytokine syndrome-like clinical presentation in human immunodeficiency virus-infected children in Malawi","volume":"69","author":"El-Mallawany","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2025112508561948900_bib26","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1016\/j.amjmed.2021.04.015","article-title":"The importance of early recognition of KSHV-mediated syndromes: a case report","volume":"134","author":"Spezia-Lindner","year":"2021","journal-title":"Am J Med"},{"issue":"10","key":"2025112508561948900_bib27","doi-asserted-by":"crossref","first-page":"e1566","DOI":"10.1016\/S2214-109X(23)00349-2","article-title":"Global patterns and trends in Kaposi sarcoma incidence: a population-based study","volume":"11","author":"Fu","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2025112508561948900_bib28","doi-asserted-by":"publisher","first-page":"2024.08.26.24312536","DOI":"10.1101\/2024.08.26.24312536","article-title":"Survival following diagnosis of HIV-associated Kaposi sarcoma among adults in East Africa in the \u201cTreat-All\u201d era","author":"Byakwaga","year":"2024","journal-title":"medRxiv"},{"issue":"5","key":"2025112508561948900_bib29","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/infdis\/jiz180","article-title":"The contribution of Kaposi\u2019s sarcoma\u2013associated herpesvirus to mortality in hospitalized human immunodeficiency virus\u2013infected patients being investigated for tuberculosis in South Africa","volume":"220","author":"Blumenthal","year":"2019","journal-title":"J Infect Dis"},{"key":"2025112508561948900_bib30","volume-title":"International Conference on Malignancies in HIV\/AIDS","author":"Muwando","year":"2024","edition":"19th ed"},{"issue":"14","key":"2025112508561948900_bib31","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1097\/QAD.0000000000003333","article-title":"Characteristics of patients admitted to the ICU with Kaposi sarcoma herpesvirus-associated diseases","volume":"36","author":"Hansen","year":"2022","journal-title":"AIDS"},{"issue":"22","key":"2025112508561948900_bib32","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1200\/JCO.2005.14.597","article-title":"Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma","volume":"23","author":"Bower","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025112508561948900_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12981-017-0156-9","article-title":"Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma","volume":"14","author":"Volkow","year":"2017","journal-title":"AIDS Res Ther"},{"issue":"4","key":"2025112508561948900_bib34","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/cancers14040986","article-title":"Immune reconstitution inflammatory syndrome associated Kaposi sarcoma","volume":"14","author":"Poizot-Martin","year":"2022","journal-title":"Cancers"},{"issue":"26","key":"2025112508561948900_bib35","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/bloodadvances.2017012310","article-title":"Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH","volume":"1","author":"Hayden","year":"2017","journal-title":"Blood Adv"},{"issue":"9","key":"2025112508561948900_bib36","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"2025112508561948900_bib37","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1182\/blood.V98.10.3042","article-title":"Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma\u2013associated herpesvirus: Presented in part at the 42nd annual meeting of the American Society of Hematology, December 4, 2000, in San Francisco, CA","volume":"98","author":"Aoki","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2025112508561948900_bib38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1186\/s12967-023-04517-5","article-title":"Transcriptional landscape of Kaposi sarcoma tumors identifies unique immunologic signatures and key determinants of angiogenesis","volume":"21","author":"Ramaswami","year":"2023","journal-title":"J Transl Med"},{"issue":"14","key":"2025112508561948900_bib39","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/blood.2024024144","article-title":"Inflammasome activation in patients with Kaposi sarcoma herpesvirus\u2013associated diseases","volume":"144","author":"Lage","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2025112508561948900_bib40","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1182\/bloodadvances.2022008456","article-title":"Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease","volume":"7","author":"Martin de Fr\u00e9mont","year":"2023","journal-title":"Blood Adv"},{"issue":"18","key":"2025112508561948900_bib41","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1200\/JCO.2010.34.1909","article-title":"Clinical features and outcome in HIV-associated multicentric Castleman's disease","volume":"29","author":"Bower","year":"2011","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025112508561948900_bib42","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2007.10.6732","article-title":"Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus\u2013associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial","volume":"25","author":"G\u00e9rard","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025112508561948900_bib43","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/0003-4819-147-12-200712180-00003","article-title":"Brief communication: rituximab in HIV-associated multicentric Castleman disease","volume":"147","author":"Bower","year":"2007","journal-title":"Ann Intern Med"},{"issue":"12","key":"2025112508561948900_bib44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/tropicalmed9120307","article-title":"Diagnosis and management of Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome in resource-constrained settings: a case report and an adapted case definition","volume":"9","author":"Kumwenda","year":"2024","journal-title":"Trop Med Infect Dis"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5720\/2419912\/blooda_adv-2025-016685-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5720\/2419912\/blooda_adv-2025-016685-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:56:28Z","timestamp":1764078988000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/22\/5720\/546494\/Characteristics-and-outcomes-of-Kaposi-sarcoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":44,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016685","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,25]]},"published":{"date-parts":[[2025,11,12]]}}}